![](/images/graphics-bg.png)
Myxedema Coma: A Life-Threatening Condition in Patients Using Pembrolizumab
Joint Authors
Phillips, Brian
Gummalla, Sangeetha
Manjunath, Madhura
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-2, 2 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-10-22
Country of Publication
Egypt
No. of Pages
2
Main Subjects
Abstract EN
The advent of immune checkpoint inhibitors has significantly improved the prognosis of patients with advanced malignancies.
As we begin to understand these medications, multiple immune-related adverse effects (irAEs) have been found with these drugs, including endocrinopathies.
Understanding the treatment-related adverse events of these medications is critical for clinical practice.
Thyroid-related adverse effects usually occur within the first three months of treatment and rarely after eight months.
It can manifest as an early onset of thyrotoxicosis, which is largely asymptomatic, followed by a rapid transition to hypothyroidism, requiring long-term levothyroxine substitution.
We present a case in which our patient was found unresponsive, hypothermic, and with respiratory failure almost after completing a year of treatment with pembrolizumab.
He had an initial mild elevation in thyroid-stimulating hormone (TSH) of 6.52, although with normal free thyroxine (T4) of 1.06, in his first three months of starting treatment which then rapidly progressed to a true myxedema coma.
The infrequency with which this occurs makes it a diagnostic challenge.
American Psychological Association (APA)
Gummalla, Sangeetha& Manjunath, Madhura& Phillips, Brian. 2020. Myxedema Coma: A Life-Threatening Condition in Patients Using Pembrolizumab. Case Reports in Endocrinology،Vol. 2020, no. 2020, pp.1-2.
https://search.emarefa.net/detail/BIM-1147127
Modern Language Association (MLA)
Gummalla, Sangeetha…[et al.]. Myxedema Coma: A Life-Threatening Condition in Patients Using Pembrolizumab. Case Reports in Endocrinology No. 2020 (2020), pp.1-2.
https://search.emarefa.net/detail/BIM-1147127
American Medical Association (AMA)
Gummalla, Sangeetha& Manjunath, Madhura& Phillips, Brian. Myxedema Coma: A Life-Threatening Condition in Patients Using Pembrolizumab. Case Reports in Endocrinology. 2020. Vol. 2020, no. 2020, pp.1-2.
https://search.emarefa.net/detail/BIM-1147127
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1147127